We anticipate that primary liver cancer or liver metastasis of other tumor types would be ideal indications to test this new therapeutic approach in the clinic on the basis of (i) exosome biodistribution showing that 95% of the injected dose accumulates in the liver, (ii) enhanced Stat6 knockdown in liver tissue associated with intravenous exosome-mediated delivery of ASO, (iii) significant antitumoral efficacy of exoASO-STAT6 in the HCC model, and (iv) poor survival in human patients with HCC with high STAT6 transcriptional signature. The gene discussed is STAT6; the disease is hepatocellular carcinoma.